Table 1 Demographic characteristics of patient samples

N

18

12

20

Age at sampling (years)

67 [61–73]

71 [59–74]

63 [59–67]

0.266

Sex (male/female)

11/7

5/7

13/7

0.409

CSF Aβ42 (pg/mL)

536

[469–569]

(n = 11)

-

1072

[908–1154]

(n = 20)

< 0.0001

CSF t-tau (pg/mL)

830

[617–1136]

(n = 11)

-

324

[283–514]

(n = 20)

< 0.001

CSF p-tau181 (pg/mL)

111 [63–164]

(n = 11)

-

54 [39–60]

(n = 20)

< 0.05

MMSE

19 [16–25]

(n = 15)

29 [28–30]

(n = 11)

25 [23.5–27]

(n = 19)

< 0.0001

Plasma GFAP (pg/mL)

282 [186–377]

130 [96–191]

127 [105–164]

< 0.001

Plasma NfL (pg/mL)

31.5 [21.9–38.8]

15.2 [13.4–23.9]

51.7 [28.2–77.8]

< 0.01

Plasma pTau-181 (pg/mL)

2.11 [1.84–2.64]

1.17 [1.02–1.31]

0.98 [0.78–1.26]

< 0.0001

Plasma Aβ40 Simoa, (pg/mL)

222 [201–254]

(n = 16)

231 [211–314]

(n = 12)

206 [178–235]

(n = 19)

0.097

Plasma Aβ40 Shimadzu (pg/mL)

8.01 [6.27–8.84]

8.11 [6.82–9.23]

7.34 [6.60 − 8.54]

0.723

Plasma Aβ40 Ulm (pg/mL)

455 [410–484]

452 [423–573]

452 [400–487]

0.671

Plasma Aβ42 Simoa (pg/mL)

8.94 [8.03–9.79]

(n = 16)

10.0 [8.96–12.9]

(n = 12)

9.19 [7.95–10.8]

(n = 19)

0.313

Plasma Aβ42 Shimadzu (pg/mL)

0.35 [0.32–0.41]

0.38 [0.38–0.44]

0.36 [0.32–0.39]

0.079

Plasma Aβ42 Ulm (pg/mL)

58.8 [54.9–64.0]

68.1 [63.0–82.5]

57.7 [53.6–65.6]

< 0.05

Plasma Aβ42/40 Simoa

0.039 [0.036–0.041]

(n = 16)

0.040 [0.037–0.047]

(n = 12)

0.046 [0.042–0.051]

(n = 19)

< 0.05

Plasma Aβ42/40 Shimadzu

0.044 [0.042–0.051]

0.048 [0.045–0.055]

0.048 [0.042 − 0.052

0.372

Plasma Aβ42/40 Ulm

0.131 [0.123–0.138]

0.145 [0.139 − 0.167]

0.130 [0.125–0.142]

< 0.01

Shimadzu composite score

0.719 [0.028–1.12]

-0.126 [-0.473–0.136]

0.281 [-0.222–0.661]

< 0.05